NC's Biotech Boom: Cape Fear BioCapital Closes Fund I to Fuel Local Innovation

RESEARCH TRIANGLE PARK, NC – September 03, 2026 – In a move that signals a significant maturation of North Carolina’s life sciences ecosystem, Cape Fear BioCapital today announced the final close of its inaugural fund. While any new venture fund brings a welcome infusion of capital, Fund I represents something more profound: a meticulously engineered vehicle designed not just to fund, but to build world-class therapeutics companies from the ground up, right here in the Tar Heel State.

The fund, anchored by Moore Strategic Ventures—the private investment arm of North Carolina native and Moore Capital Management founder Louis M. Bacon—has deliberately assembled a syndicate that values expertise as highly as capital. By bringing in strategic partners like global clinical research organization (CRO) Parexel and a curated group of the state's most successful biotech founders and executives, Cape Fear is tackling a long-standing challenge for the region: bridging the gap between world-class academic research and venture-backable, globally competitive enterprises. This isn't just about writing checks; it's about building an engine for sustained innovation.

Beyond the Checkbook: A New Model for Company Building

For years, the narrative around North Carolina’s biotech scene has been consistent: brilliant science and a deep talent pool, but a deficit in the early-stage capital and seasoned operational leadership needed to keep promising ventures from leaving the state or fizzling out. Cape Fear BioCapital was founded to rewrite that story.

“When we launched, we said North Carolina had everything it needed to build world-class biotech companies except access to early capital and the operators who’ve done it before,” said Ed Field, a General Partner at the firm. “The opportunity is clearer than ever, and expanding the fund lets us bring on exactly the founders and leaders needed to back the North Carolina entrepreneurs seeking to build their startups.”

This philosophy is the core of the firm’s “hands-on” model. Led by General Partners Ed Field, Jimmy Melton, and Dave Ousterout—who collectively bring deep experience in company building, scientific innovation, and venture finance—the firm focuses on writing the crucial "first check" for seed-stage companies. Field’s track record includes building out BioLabs NC, now the largest life science innovation hub in the Southeast, which has supported over 90 startups that have collectively raised more than $2 billion. Ousterout, a co-founder of Locus Biosciences, brings firsthand experience in translating novel protein engineering technology from a Duke University lab into a clinical-stage company.

This operational DNA is amplified by the fund's limited partners. Instead of relying solely on institutional investors, Cape Fear has enlisted individuals who have navigated the treacherous path of biotech entrepreneurship themselves. Among them is Brendan Griffin, who successfully guided Propella Therapeutics to a $175 million acquisition by Astellas Pharma in 2023.

“As an operator who successfully built and exited a biotech company in North Carolina, I’ve seen the need for strong early support,” Griffin stated. “I invested with Cape Fear to contribute both capital and my operating experience to our most promising startups so they can grow here, while also backing a compelling approach to driving value creation.” This model creates a powerful feedback loop, where the successes of one generation of North Carolina biotech leaders directly fuel the next.

The Power of the Strategic Network

A key differentiator for Cape Fear BioCapital is its cultivation of a powerful support ecosystem. The partnership with Parexel, a global leader in clinical development headquartered in the state, is a prime example. In June, the two organizations launched the Parexel Biotech Incubator, an initiative designed to give nascent companies an unparalleled advantage.

The incubator provides portfolio companies with direct access to Parexel's vast clinical and regulatory expertise, helping them navigate the complex journey from early discovery to filing for an Investigational New Drug (IND) application. This collaboration addresses a critical failure point for many startups, which often lack the resources or knowledge to design effective clinical development strategies. By embedding this expertise at the seed stage, the partnership aims to de-risk investments and significantly accelerate timelines.

The anchor investment from Moore Strategic Ventures provides not only substantial financial backing but also a vote of confidence from a major global investment firm with deep North Carolina roots. This strategic alignment ensures that the fund has the long-term, patient capital required for the lengthy development cycles inherent in therapeutics. Together, these partnerships create a robust infrastructure that provides far more than money—they offer a clear pathway to critical milestones.

Validating the Thesis: Early Wins and Future Ambitions

Since its launch in late 2024, Cape Fear has already demonstrated the potency of its approach. From a pool of over 200 early-stage opportunities, the firm has made seven investments, with the newly expanded Fund I providing capacity for another three to five. The portfolio reflects a diverse range of cutting-edge science emerging from the state's research hubs, including an AI-enabled drug discovery platform (Ten63 Therapeutics), a clinical-stage oncology asset (Incyclix Bio), and a novel surgical device for cardiothoracic procedures (Thoracic Innovations).

Crucially, these companies are already hitting milestones and securing follow-on funding, validating the firm's core thesis. This momentum is a testament to the hands-on model. Mike Dombeck, CEO of portfolio company EnFuego Therapeutics, highlighted this direct impact. “Cape Fear relentlessly focused on bringing both capital and experience to this venture,” he said. “They wrote the first institutional check and brought me in to drive the company's drug candidates towards clinical development. We share founder Dr. Chad Pecot's deep conviction to translate his research into transformative medicines for cancer patients.”

This early success has set the stage for what comes next. The firm has a stated ambition of launching a second, larger fund and investing in more than 40 seed-stage companies within its first decade. Such a scale would fundamentally alter the landscape, creating a self-sustaining cycle of innovation, investment, and talent retention in North Carolina. By systematically identifying promising science and pairing it with experienced leadership and strategic resources, Cape Fear BioCapital is not just funding companies—it is actively constructing the pillars of the state's future as a global biotech powerhouse.